Home LiteratureArticle Details
PMID: 15681404 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.

Journal of virology ·Vol. 79 ·No. 4 ·2005-02-00 ·Pages 2024-32

Oumouna M, Mapletoft JW, Karvonen BC, Babiuk LA, van Drunen Littel-van den Hurk S

Abstract

Commercial killed bovine respiratory syncytial virus (K-BRSV) and formalin-inactivated BRSV (FI-BRSV) tend to induce Th2-type immune responses, which may not be protective and may even be detrimental during subsequent exposure to the virus. In this study we assessed the ability of CpG oligodeoxynucleotides (ODNs) to aid in the generation of effective and protective BRSV-specific immune responses. Mice were immunized subcutaneously with FI-BRSV formulated with CpG ODN, Emulsigen (Em), CpG ODN and Em, or non-CpG ODN and Em. Two additional groups were immunized with K-BRSV or K-BRSV and CpG ODN. After two vaccinations, the mice were challenged with BRSV. FI-BRSV induced Th2-biased immune responses characterized by production of serum immunoglobulin G1 (IgG1) and IgE, as well as interleukin-4 (IL-4), by in vitro-restimulated splenocytes. Formulation of FI-BRSV with CpG ODN, but not with non-CpG ODN, enhanced serum IgG2a and IFN-gamma production by splenocytes, whereas serum IgE was reduced. Although the immune response induced by K-BRSV was not as strongly Th2 biased, the addition of CpG ODN to this commercial vaccine also resulted in a more Th1-type response. Furthermore, the addition of CpG ODN to the BRSV vaccine formulations resulted in enhanced neutralizing antibody responses. Significant production of IL-5, eotaxin, and eosinophilia was observed in the lungs of FI-BRSV- and K-BRSV-immunized mice. However, IL-5 and eotaxin levels, as well as the number of eosinophils, were decreased in the mice vaccinated with the CpG ODN-formulated vaccines. Finally, when formulated with CpG ODN, both FI-BRSV and K-BRSV significantly reduced virus production after challenge with BRSV.

MeSH Terms
Adjuvants, Immunologic/administration & dosage Animals Cell Line Chemistry, Pharmaceutical Formaldehyde/pharmacology Immunization Immunoglobulin G/biosynthesis Interferon-gamma/biosynthesis,blood Mice Mice, Inbred BALB C Oligodeoxyribonucleotides/administration & dosage,chemistry,immunology Respiratory Syncytial Virus Infections/immunology,prevention & control,veterinary Respiratory Syncytial Virus, Bovine/drug effects,immunology Vaccines, Attenuated/administration & dosage,immunology Viral Proteins Viral Vaccines/administration & dosage,immunology
Chemicals
Adjuvants, Immunologic CPG-oligonucleotide Immunoglobulin G Oligodeoxyribonucleotides Vaccines, Attenuated Viral Proteins Viral Vaccines bovine herpesvirus type-1 glycoproteins Formaldehyde Interferon-gamma
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Oumouna M
Vaccine and Infectious Disease Organization, University of Saskatchewan, 120 Veterinary Rd., Saskatoon, Saskatchewan S7N 5E3, Canada.
Mapletoft J W
Karvonen B C
Babiuk L A
van Drunen Littel-van den Hurk S
References (64)
64 references, click to expand
  1. Interferon-gamma: a review.
    Immunobiology. 1989 Oct;179(4-5):456-73 PMID: 2515154
  2. Immunity to human and bovine respiratory syncytial virus.
    Arch Virol. 1990;112(1-2):1-25 PMID: 2196033
  3. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.
    Int Immunol. 1992 Apr;4(4):493-500 PMID: 1591217
  4. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Vaccine. 1992;10(7):475-84 PMID: 1609551
  5. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.
    J Virol. 1992 Dec;66(12):7444-51 PMID: 1433525
  6. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.
    J Immunol. 1993 Aug 15;151(4):2032-40 PMID: 8345194
  7. Mechanism and function of a newly identified CpG DNA motif in human primary B cells.
    J Immunol. 2000 Jan 15;164(2):944-53 PMID: 10623843
  8. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
    J Immunol. 2000 Feb 1;164(3):1617-24 PMID: 10640783
  9. The role of CpG motifs in innate immunity.
    Curr Opin Immunol. 2000 Feb;12(1):35-43 PMID: 10679406
  10. Bovine respiratory syncytial virus-specific IgE is associated with interleukin-2 and -4, and interferon-gamma expression in pulmonary lymph of experimentally infected calves.
    Am J Vet Res. 2000 Mar;61(3):291-8 PMID: 10714521
  11. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.
    Am J Respir Crit Care Med. 2000 May;161(5):1501-7 PMID: 10806145
  12. Asthma.
    N Engl J Med. 2001 Feb 1;344(5):350-62 PMID: 11172168
  13. Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development.
    Vaccine. 2001 Apr 6;19(20-22):2769-82 PMID: 11282187
  14. Best minimally modified antisense oligonucleotides according to cell nuclease activity.
    Antisense Nucleic Acid Drug Dev. 2001 Jun;11(3):129-36 PMID: 11446588
  15. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).
    Vaccine. 2001 Sep 14;19(32):4874-82 PMID: 11535341
  16. Persistent infection of B lymphocytes by bovine respiratory syncytial virus.
    Virology. 2001 Dec 5;291(1):55-67 PMID: 11878876
  17. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.
    J Immunol. 2002 Jun 15;168(12):6099-105 PMID: 12055220
  18. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides.
    J Virol. 2002 Sep;76(18):9002-10 PMID: 12186884
  19. A role for immune complexes in enhanced respiratory syncytial virus disease.
    J Exp Med. 2002 Sep 16;196(6):859-65 PMID: 12235218
  20. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
    Vaccine. 2002 Nov 22;21(1-2):127-37 PMID: 12443671
  21. Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus.
    Am J Pathol. 2002 Dec;161(6):2195-207 PMID: 12466134
  22. An experimental infection model for reproduction of calf pneumonia with bovine respiratory syncytial virus (BRSV) based on one combined exposure of calves.
    Res Vet Sci. 2003 Feb;74(1):55-65 PMID: 12507567
  23. Development of short non-CpG phosphodiester oligonucleotides as immune stimulatory agents.
    Vaccine. 2003 Feb 14;21(9-10):983-9 PMID: 12547612
  24. The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus.
    Vaccine. 1994;12(3):267-74 PMID: 8165859
  25. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.
    J Virol. 1994 Aug;68(8):5321-5 PMID: 8035532
  26. Association of interleukin-5 and eotaxin with acute exacerbation of asthma.
    Int Arch Allergy Immunol. 2003 Aug;131(4):283-90 PMID: 12915771
  27. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.
    J Virol. 2003 Sep;77(18):9831-44 PMID: 12941892
  28. Role of the chemokines RANTES, monocyte chemotactic proteins-3 and -4, and eotaxins-1 and -2 in childhood asthma.
    Eur Respir J. 2003 Aug;22(2):310-6 PMID: 12952266
  29. Safety of CpG oligodeoxynucleotides in veterinary species.
    Antisense Nucleic Acid Drug Dev. 2003;13(3):157-67 PMID: 12954116
  30. Adjuvant formulations and delivery systems for DNA vaccines.
    Methods. 2003 Nov;31(3):243-54 PMID: 14511957
  31. IkappaB kinase is a critical regulator of chemokine expression and lung inflammation in respiratory syncytial virus infection.
    J Virol. 2004 Mar;78(5):2232-41 PMID: 14963119
  32. Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma.
    Int Immunopharmacol. 2004 Jan;4(1):127-38 PMID: 14975367
  33. Immunotherapeutic uses of CpG oligodeoxynucleotides.
    Nat Rev Immunol. 2004 Apr;4(4):249-58 PMID: 15057783
  34. Formalin-inactivated bovine RSV vaccine enhances a Th2 mediated immune response in infected cattle.
    Vaccine. 2004 Mar 29;22(11-12):1465-74 PMID: 15063570
  35. Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine.
    Am Rev Respir Dis. 1966 Sep;94(3):362-79 PMID: 4288226
  36. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.
    Am J Epidemiol. 1969 Apr;89(4):422-34 PMID: 4305198
  37. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.
    Am J Epidemiol. 1969 Apr;89(4):435-48 PMID: 4305199
  38. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.
    Am J Epidemiol. 1969 Apr;89(4):449-63 PMID: 4305200
  39. The appearance of cell-bound IgE in respiratory-tract epithelium after respiratory-syncytial-virus infection.
    N Engl J Med. 1980 Nov 20;303(21):1198-202 PMID: 7421946
  40. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection.
    N Engl J Med. 1981 Oct 8;305(15):841-6 PMID: 6168908
  41. Respiratory syncytial virus pneumonia in young calves: clinical and pathologic findings.
    Am J Vet Res. 1983 Sep;44(9):1648-55 PMID: 6625318
  42. Respiratory syncytial virus. Brief review.
    Arch Virol. 1985;84(1-2):1-52 PMID: 3885919
  43. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    J Virol. 1987 Dec;61(12):3855-61 PMID: 3316707
  44. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.
    J Clin Microbiol. 1988 Aug;26(8):1595-7 PMID: 2459154
  45. Activation of complement by bovine respiratory syncytial virus-infected cells.
    Vet Immunol Immunopathol. 1989 Jul;21(3-4):311-25 PMID: 2800328
  46. A severe outbreak of respiratory tract disease associated with bovine respiratory syncytial virus probably enhanced by vaccination with modified live vaccine.
    Vet Q. 1989 Oct;11(4):250-3 PMID: 2603358
  47. Respiratory syncytial virus infections in human beings and in cattle.
    J Infect. 1994 Sep;29(2):215-28 PMID: 7806887
  48. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
    Vaccine. 1995 Mar;13(4):391-400 PMID: 7793137
  49. Comparison of the T helper cell response induced by respiratory syncytial virus and its fusion protein in BALB/c mice.
    Vaccine. 1995 Jul;13(10):915-22 PMID: 7483764
  50. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.
    Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 2):S63-6 PMID: 7551416
  51. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.
    Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83 PMID: 8610135
  52. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
    J Immunol. 1996 Sep 1;157(5):1840-5 PMID: 8757300
  53. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.
    J Virol. 1996 Nov;70(11):7783-91 PMID: 8892899
  54. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
    J Exp Med. 1997 Nov 17;186(10):1623-31 PMID: 9362523
  55. Bovine respiratory syncytial virus.
    Vet Clin North Am Food Anim Pract. 1997 Nov;13(3):425-54 PMID: 9368988
  56. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
    J Immunol. 1998 Jan 15;160(2):870-6 PMID: 9551923
  57. Resistance to bovine respiratory syncytial virus (BRSV) induced in calves by a recombinant bovine herpesvirus-1 expressing the attachment glycoprotein of BRSV.
    J Gen Virol. 1998 Jul;79 ( Pt 7):1759-67 PMID: 9680140
  58. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge.
    J Immunol. 1998 Sep 1;161(5):2428-34 PMID: 9725240
  59. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
    J Immunol. 1998 Sep 15;161(6):3042-9 PMID: 9743369
  60. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.
    Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8 PMID: 9861007
  61. Interferon gamma production during bovine respiratory syncytial virus (BRSV) infection is diminished in calves vaccinated with formalin-inactivated BRSV.
    Vaccine. 1999 Mar 17;17(11-12):1293-7 PMID: 10195762
  62. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment.
    Clin Microbiol Rev. 1999 Apr;12(2):298-309 PMID: 10194461
  63. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms.
    Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6970-5 PMID: 10359823
  64. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.
    Lancet. 1999 Aug 14;354(9178):541-5 PMID: 10470697
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2005-02-00
Pages
2024-32
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC546558
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]